Navigation Links
Life Technologies Announces Third Quarter 2012 Results
Date:11/1/2012

one-time costs including the early repayment of debt and the associated impacts, and the impact of certain settlements in order to provide a supplemental comparison of the results of operations.  LIFE TECHNOLOGIES CORPORATIONCONSOLIDATED STATEMENTS OF OPERATIONSFor the nine monthsFor the nine months(in thousands, except per share data)ended September 30, 2012ended September 30, 2011(unaudited)Revenues$
2,799,606$
2,765,227Cost of revenues

955,111955,840Purchased intangibles amortization

219,192226,527Gross profit

1,625,3031,582,860Gross margin58.1%57.2%Operating expenses:Selling, general and administrative

790,012759,438Research and development

258,225287,723Business consolidation costs

34,26656,468Total operating expenses

1,082,5031,103,629Operating income

542,800479,231Operating margin

19.4%17.3%Interest income

1,7152,960Interest expense

(94,266)(123,911)Other expense, net

(11,097)(7,980)Total other expense, net

(103,648)(128,931)Income from operations before provision for income taxes

439,152350,300Income tax provision

(87,083)(65,534)Net income

352,069284,766Net loss attributable to non-controlling interests

305658Net income attributable to controlling interest$
352,374$
285,424Effective tax rate 

19.8%18.7%Add back interest expense for subordinateddebt, net of tax

12716Numerator for diluted earnings  per share$
352,386$
286,140Earnings per common share:Basic earnings per share attributable to controlling interest$
.99$
.59Diluted earnings per share attributable to controlling interest$
.95$
.54Weighted average shares used in per share calculation:Basic

177,028179,751Diluted

180,559185,946 

 

 LIFE TECHNOLOGIES CORPORA
'/>"/>

SOURCE Life Technologies Corporation
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. UV Flu Technologies Expands Its International Footprint
3. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
4. OrthoAccel® Technologies, Inc. Announces Definitive Distribution Agreement in Italy
5. Hologic to Showcase 3D Mammography (Breast Tomosynthesis) and Other Advanced Womens Imaging Technologies at RSNA 2011, the Largest Radiology Show in the World
6. Modern Mobility Aids, Inc. Secures Financing to Close Acquisition Agreement of LumiGene Technologies
7. Senesco Technologies, Inc. to Webcast, Live, at RetailInvestorConferences.com on December 1st
8. Animal Biotechnology - Technologies, Markets and Companies
9. Gene Therapy - Technologies, Markets and Companies
10. Biomarkers - Technologies, Markets and Companies
11. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Raleigh, NC (PRWEB) June 19, 2013 ... and eclinical commerce network for clinical trials, today ... technology at DIA 2013 (booth #2000) in Boston, ... is the industry’s first and only fully configurable, ... technology, ClinPay®, the flagship module within Clinverse’s eClinical ...
(Date:6/19/2013)... 19, 2013  Continuing its long history of proven ... Beckman Coulter , Inc. announces the U.S. Food and ... AccuTnI+3 troponin I assay for use on its Access ... on Beckman Coulter,s troponin I test for ... the proven performance to continue providing dependability to laboratories ...
(Date:6/19/2013)... 2013 Today DuPont Executive Vice President ... become leaders in the greatest challenge facing our time ... 2050. Borel spoke at the International Food ... about urgent need for students to contribute their time ... sustainable and reached in collaboration with others. , “Food ...
(Date:6/19/2013)... Bloomington, Indiana (PRWEB) June 19, 2013 ... Valentine joined the speaking faculty at 2013’s BioLogistics ... , The conference, coordinated by Cold Chain IQ ... surrounding biologics. This “complexity” is, in part, attributed ... medicine. , “Implicit within these trends is ...
Breaking Biology Technology:Clinverse, Inc. Exhibiting and Showcasing Its Technology at DIA 2013 2Beckman Coulter Announces FDA Clearance of New Access AccuTnI+3 Troponin I Assay for the Access 2 Immunoassay System 2Beckman Coulter Announces FDA Clearance of New Access AccuTnI+3 Troponin I Assay for the Access 2 Immunoassay System 3DuPont Leader Calls for New Generation of Food Visionaries to Fight Hunger 2BioConvergence® Presents at BioLogistics Summit on Risk Matrix for Biosamples during Shipment 2
... Chindex International,Inc. (Nasdaq: CHDX ), an independent ... products in the People,s,Republic of China, today announced ... ended March 31, 2008., For the 2008 ... $130.1,million, an increase of 23% over the prior ...
... Takes Prominent Position and ... WEST SENECA, N.Y., June 11 Palladian Muscular Skeletal,Health ... a high-profile presence at a leading healthcare event -- ... June,18 to Friday, June 20, 2008., "We have ...
... Rosetta Genomics has Signed a Binding Term Sheet to Acquire Parkway ... ... Significantly Streamline the Development and Commercialization of Rosetta Genomics, microRNA-based ... Needs to Market and Sell its microRNA-based Tests in the U.S. and ...
Cached Biology Technology:Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results 2Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results 3Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results 4Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results 5Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results 6Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results 7Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results 8Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results 9Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results 10Palladian Muscular Skeletal Health (formerly Prism Health Networks) to Promote Collaborative, Expanded Practice Model at Major Insurance Conference in June 2Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests 2Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests 3Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests 4Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests 5Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests 6
(Date:6/19/2013)... June 19, 2013 A study published in the ... the first report of an oral probiotic supplement significantly ... , The lead author on the study, Mitchell ... Presentation Prize from the New York Academy of Sciences ... week,s Probiotics, Prebiotics, and the Host Microbiome: The ...
(Date:6/19/2013)... the Marine Biological Laboratory (MBL), Woods Hole, Massachusetts, ... by the American Society for Microbiology (ASM). ... and the scientists who worked there that have ... microbiology. A ceremony unveiling the plaque that ... June 22, 2013, at 4:30 pm in the ...
(Date:6/19/2013)... A team of researchers at the University of ... outer coating of HIV, that could be potential ... avoid generating resistance. These new agents are quite ... The research was published in the June 2013 ... Chemotherapy . , The first of many probable ...
Breaking Biology News(10 mins):Study shows probiotic Lactobacillus reuteri NCIMB 30242 significantly increased vitamin D levels 2Microbial diversity course designated as a 'Milestones in Microbiology' site 2HIV-derived antibacterial shows promise against drug-resistant bacteria 2
... under scrutiny lately due to adverse cardiovascular side-effects stemming ... models, researchers reveal another adverse effect of Celecoxib; this ... independent of the COX-2 enzyme. Satpal Singh ... rate of Drosophila, a good model for human cardiac ...
... friends used to think he was eccentric, crawling like ... Pennsylvania, hauling dental tools and a jack hammer. ... gotten over it, and are congratulating him on receiving ... Society, presented at the Geological Society of Americas recent ...
... of medical and scientific books and journals, was ... content is immediately available on www.springerlink.com ... and more than 22,000 eBooks. Beginning with the ... purchase Humana Press journals through Springer. All issues ...
Cached Biology News:Academy volunteer wins national paleontology award 2Humana Press journals now available on SpringerLink 2
... Rabbit polyclonal to Taura ... Abpromise for all tested ... Synthetic peptide: VTNSEGSTIL MNDIPITNQN ... ATEFNQ, corresponding to N terminal ...
Goat polyclonal to SART3 ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSNADFAKLFLRK, corresponding to C terminal amino acids 951-963 of Human SART3 Entrez Gene ID: 9...
... Immunogen: KLH-conjugated, synthetic peptide ... which [ Ac K] corresponds to acetyl ... Accession Number: NM_003493 ... Quality Assurance: Routinely ...
Blank Calibration Particles, 3.0-3.4 mu m 5 ml...
Biology Products: